SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support
SK bioscience Secures Funding to Advance RSV Preventive Antibody Development RIGHT Foundation will provide KRW 4 billion in support to SK bioscience for the “Development of an Affordable Monoclonal Antibody for RSV Prevention” project. Largest-ever grant from RIGHT Foundation to accelerate Phase 1b clinical trial of RSV preventive antibodyTechnolog...
EuBiologics’ typhoid conjugate vaccine shows non-inferior efficacy in phase 3 Africa trial
EuBiologics’ typhoid conjugate vaccine shows non-inferior efficacy in phase 3 Africa trial RIGHT Foundation has supported EuBiologics’ typhoid conjugate vaccine development since 2021 and will provide total funding of approximately KRW 5.7 billion through 2026. Korean vaccine developer EuBiologics said it has published the phase 3 multinational cli...
CARB-X New Funding Round Announced
Details and links to CARB-X funding call: Apply Here: https://carb-x.org/apply/apply-here/ Product themes and eligibility criteria FAQs and webinar slides Partner News List
Noul’s miLab, First Product Listing Completed with US FDA
Noul’s miLab, US Market Expansion in Full Swing∙∙∙First Product Listing Completed with US FDA The RIGHT Foundation has been supporting Noul’s diagnostic device, miLab, since 2020 through the project titled “AI-driven all-in-one diagnostic platform for malaria species differentiation” A total of 4.3 billion KRW in funding will be p...